Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Holding CRBP?
Track your performance easily
CRBP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.03 - $61.90
Previous Close$21.35
Volume1.03M
Average Volume (3M)580.55K
Market Cap
$258.10M
Enterprise Value$124.91M
Total Cash (Recent Filing)$147.03M
Total Debt (Recent Filing)$14.80M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Nov 05, 2024EPS Estimate
-$0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.82
Shares Outstanding12,043,940
10 Day Avg. Volume2,083,603
30 Day Avg. Volume580,548
Standard Deviation0.54
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.05
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$84.29Price Target Upside293.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Corbus Pharmaceuticals News
PremiumCompany Announcements
Corbus Pharmaceuticals Announces Board Changes and New Compensation Plans
Bulls Say, Bears Say
Bulls Say
Clinical DataThe data presented at EASD suggests that CRBP's '913 could have fewer gastrointestinal-related adverse events compared to GLP-1-based therapies.
Market OpportunityThe company’s strategy to develop a next-generation weight loss agent could address the unmet needs of available drugs.
Product DifferentiationCRB-701’s more convenient dosing regimen, cleaner safety profile to date, and possibly greater efficacy are meaningful differentiators.
Bears Say
Clinical Trial ResultsBoth efficacy and safety/tolerability data were admittedly disappointing, and further, with NVO only providing relatively scant details, there are more questions than answers about the potential of this next class of CB1 blockers.
Regulatory RisksRisks include: negative data for proprietary candidates; superior competitor data; development/regulatory timeline delays; and negative sentiment on the biotech sector.
Safety ConcernsMild to moderate neuropsychiatric side effects, primarily anxiety, irritability, and sleep disturbances, were reported with an imbalance in the monlunabant treatment arm.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $3.03 and its highest was $61.90 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Currently, no data Available
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Nov 05, 2024 which is in 40 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Aug 06, 2024. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$1.188 by $0.288.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -$0.95.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 12,043,940 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$0.9 in its last earnings report, beating expectations of -$1.188. Following the earnings report the stock price went down -3.798%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Among the largest hedge funds holding Corbus Pharmaceuticals’s share is Woodline Partners LP. It holds Corbus Pharmaceuticals’s shares valued at 11M.
---
Corbus Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.29 (293.33% Upside)
$84.29 (293.33% Upside)
Blogger Sentiment
Bullish
CRBP Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 263.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $7.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.5%
Last 30 Days ▲ 17.3%
Last 30 Days ▲ 17.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
252.31%
12-Months-Change
Fundamentals
Return on Equity
-51.78%
Trailing 12-Months
Asset Growth
247.59%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
---
CRBP Stock 12 Month Forecast
Average Price Target
$84.29
▲(293.33% Upside)
Technical Analysis
Anavex Life Sciences
―
Cyclacel Pharmaceuticals
―
Cytokinetics
―
Karyopharm Therapeutics
―
Best Analysts Covering CRBP
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
+10.59%
reiterated a buy rating 7 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of +10.59% per trade.
---